Administration costs of intravenous biologic drugs for rheumatoid arthritis

Soini, Erkki J; Leussu, Miina; Hallinen, Taru

doi:10.1186/2193-1801-2-531

SpringerPlus

Table 3 Statistical models for adjusted per-infusion administration costs (€2011)

From: Administration costs of intravenous biologic drugs for rheumatoid arthritis

Parameter^a	OLS (full)	OLS (sign.)	LN-OLS (full)	LN-OLS (sign.)	GLM (full)^b	GLM (sign.)^b
	*Coef. 95% CI*	*Coef. 95% CI*	*Coef. 95% CI*	*Coef. 95% CI*	*Coef. 95% CI*	*Coef. 95% CI*
University hospital	-133.07	-139.23*	-0.5129	-0.6008*	-134.57**	-172.52***
University hospital	-272.85–6.71	-252.98–-25.49	-1.1299–0.1041	-1.1449–-0.0567	-232.93–-36.21	-245.95–-99.09
District hospital^c	10.29	NR	0.1467	NR	63.02	NR
District hospital^c	-130.59–151.17		-0.2432–0.5366		-57.96–184.01
Rituximab	332.89**	332.33**	0.6370*	0.6290*	327.67***	318.99***
Rituximab	94.04–571.73	96.44–568.21	0.0591–1.2148	0.0608–1.1971	151.78–503.57	144.90–493.08
Abatacept^d	191.62*	186.47**	0.7960*	0.7225*	262.52***	245.90***
Abatacept^d	34.78–348.47	47.20–325.75	0.1767–1.4152	0.1431–1.3019	171.59–353.45	150.93–340.87
Tocilizumab^d	195.76	192.98	0.7995*	0.7598*	233.88***	230.25***
Tocilizumab^d	-57.66–449.19	-51.25–437.20	0.0938–1.5051	0.0438–1.4758	116.70–351.07	102.52–357.99
Low dose	-88.12	-86.51	-0.4786	-0.4556	-153.19***	-146.56***
Low dose	-255.55–79.30	-251.47–78.45	-0.9849–0.0277	-0.9427–0.0314	-228.44–-77.94	-221.47–-71.66
High dose	147.71*	150.86*	0.4219*	0.4669**	101.20*	110.66**
High dose	8.72–286.69	9.02–292.70	0.1041–0.7396	0.1804–0.7534	20.06–182.34	31.94–189.38
Constant	313.92***	318.71***	5.5986***	5.6668***	330.90***	363.50***
Constant	196.40–431.44	230.55–406.86	5.2776–5.9197	5.4054–5.9282	243.30–418.50	293.01–433.99
Tests
N	82	82	82	82	82	82
R²	0.29	0.29	0.29	0.28	NR	NR
Prob	0.015*	0.008**	0.002**	0.002**	NR	NR
LL	-560.38	-560.39	-86.94	-87.23	-567.96	-568.19
AIC	1136.75	1134.78	189.87	188.46	1151.92	1150.38
BIC	1156.00	1151.63	209.12	205.30	1171.18	1167.23

OLS = ordinary least squares regression model. Sign. = significant model. LN-OLS = OLS regression model with logarithmic transformation in dependent parameter. GLM = generalized linear model regression. Coef. = coefficient. 95%CI = 95% confidence interval. * p-value < 0.050. ** p-value < 0.010. *** p-value < 0.001. NR = not reported. N = number of observations. R² = coefficient of determination. Prob = model p-value. LL = log likelihood. AIC = Akaike information criteria. BIC = Bayesian information criteria. ^a Contrast is central district hospital, infliximab and indicated common adult rheumatoid arthritis dose. ^b Gamma distribution and linear link function in GLM provided the best fit among GLMs. ^c Few costs were obtained from (non-university or non-central) district hospitals. ^d Potentially biased upwards due to low number of observations.

Back to article page